Go to deals
Healthcare

ANGLE has completed a placing of new ordinary shares

ANGLE Plc has raised funds to develop the company.

ANGLE, through its subsidiaries, engages in providing products in cancer diagnostics and foetal health. Its main product is the Parsortix cell separation system, which can capture very rare cells from the blood. The company was founded by Andrew D. W. Newland in April 1994 and is headquartered in Guildford, UK.

Oaklins Cavendish’s sister firm finnCap, based in the UK, in its role as nominated advisor and joint broker, assisted ANGLE’s management team and shareholders all the way, from the start to the successful completion of the placing. During this process, the team initiated and advised on many aspects, including, among others, securing pre-commitments from cornerstone investors, seeking new institutional investors, deal structuring, document drafting, liaising with the exchange and the placing pricing and sizing.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Stuart  Andrews

Stuart Andrews

Managing Director

London, United Kingdom
Oaklins Cavendish

Related deals

Bigtincan (ASX:BTH) has raised capital to fund the acquisition of Brainshark Inc.
TMT

Bigtincan (ASX:BTH) has raised capital to fund the acquisition of Brainshark Inc.

Bigtincan Holdings Limited (ASX:BTH) has raised US$98.6 via a placement and underwritten accelerated non-renounceable entitlement offer.

Learn more
Alice Queen (ASX:AQX) has raised funds via an institutional placement
Other Industries

Alice Queen (ASX:AQX) has raised funds via an institutional placement

Alice Queen Limited (ASX:AQX) has completed a fundraising. The funds will be used to complete the Horn Island Scoping Study, accelerate exploration activities at Horn Island and support working capital. The placement was significantly oversubscribed and strongly supported by a major shareholder, as well as several existing shareholders and new institutional and sophisticated investors.

Learn more
Poolbeg Pharma has completed an Initial Public Offering on AIM
Healthcare

Poolbeg Pharma has completed an Initial Public Offering on AIM

Poolbeg Pharma Plc has raised funds to develop the company.

Learn more